How people actually get peptides.

For type 2 diabetes (Ozempic) or weight loss with BMI 27+ (Wegovy), any primary care doctor or endocrinologist can prescribe. GLP-1 telehealth providers have made this the easiest peptide to access — multiple companies will evaluate eligibility and ship from a partner pharmacy after a brief intake.

Insurance coverage is uneven for weight-loss use; some employer plans now cover Wegovy, others don't. Compounded semaglutide had a moment during the FDA shortage list, but the brand-name shortage was officially declared resolved on February 21, 2025 (tirzepatide had cleared earlier, on October 2, 2024). The 503A enforcement deadline ended April 22, 2025; the 503B deadline ended May 22, 2025. Most legitimate compounding pharmacies have stopped offering compounded semaglutide. Be skeptical of any provider still selling "compounded semaglutide" cheap — see our full analysis.

Same Rx pathway as Semaglutide, with three approved indications: type 2 diabetes (Mounjaro), weight management (Zepbound), and — since December 2024 — moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound). The OSA approval is the easiest insurance angle right now because it's a clinical diagnosis, not a BMI threshold alone.

Same compounding caveat as Semaglutide: tirzepatide was removed from the FDA shortage list on October 2, 2024, and licensed compounders are no longer permitted to make it under the shortage exception. If a clinic is still offering "compounded tirzepatide" at a discount, that's a regulatory red flag.

FDA-approved only for HIV-related visceral fat reduction. Doctors sometimes prescribe off-label for general visceral fat or fatty-liver indications, which insurance won't cover. Cash price is high. An HIV specialist or endocrinologist is the most realistic prescriber.

The only peptide-adjacent compound on this page that's available over the counter as an oral supplement. Injectable B12 (which lasts longer in the body) requires a prescription — most primary care doctors will write it if you have documented deficiency. IV/IM B12 is also commonly offered through wellness clinics, often packaged with NAD+ or hydration drips.

Oral and liposomal forms are available over the counter as supplements. Injectable and IV glutathione typically come through wellness or IV-drip clinics. Note: the FDA has issued specific consumer warnings about injectable glutathione marketed for skin lightening — that use is not approved and has been associated with adverse events including kidney issues and Stevens-Johnson syndrome.

Oral precursors (NMN, NR) are sold as supplements without a prescription. IV NAD+ is offered through wellness/longevity clinics — currently permitted under 503A compounding rules, but the FDA's evidence threshold for "longevity" claims is low to nonexistent. Subcutaneous NAD+ injections sit in the same gray space as IV.

Pen-loaded prescription medications. Norditropin and Genotropin (somatropin / human growth hormone) are prescribed for diagnosed growth hormone deficiency or AIDS-wasting — not for general anti-aging or athletic use, which is a federal offense under the Anabolic Steroid Control Act. Forteo (teriparatide) is for severe osteoporosis. All require an endocrinologist or specialist; cash prices are high.

The most-purchased research peptide, despite essentially zero published human clinical trials. Sold as a freeze-dried powder in 5–10 mg vials by online vendors. Cash price in 2026 typically lands around $35–80 per 5 mg vial depending on vendor and quantity.

The peptide compounding lobby has been pushing for FDA reclassification; the July 2026 PCAC review will likely set the next decade's status. Until then, anyone using BPC-157 is using a substance with no approved human dose, no manufacturing oversight, and no regulatory pathway in the U.S.

Same regulatory tier as BPC-157 — removed from FDA Category 2 in April 2026, awaiting PCAC review. Same vendor landscape, same diligence questions. Notable additional fact: TB-500 is on the World Anti-Doping Agency (WADA) prohibited list. If you're a competing athlete, even a single use can end your eligibility.

A three-amino-acid anti-inflammatory peptide. Mostly research has been in animal models of inflammatory bowel disease. Sold orally in capsules and as injectable peptide; topical "creams" are mostly vendor marketing without rigorous formulation. Cheaper than BPC-157.

Niche even within the research peptide world. Limited human clinical trial data. Sold by larger research peptide vendors. Not widely circulated outside longevity-focused buyers.

1970s-discovered peptide with weak modern evidence. Niche use; the sleep-peptide claim has not held up in the way the name suggests. Sold by most research peptide vendors but rarely featured.

The best research base for Epithalon comes from a single Russian lab (Khavinson group). Sold by U.S. research peptide vendors at low prices. Independent replication of the lifespan and telomerase claims is limited; the page treats this as "interesting but unconfirmed" — that framing applies to the access decision too.

Topical GHK-Cu is widely available in cosmetic skincare and is unregulated as a cosmetic ingredient — that's a different access tier (over the counter at any beauty retailer, no Rx). The injectable form sits in the U.S. research-only category, removed from FDA Cat-2 in April 2026, PCAC review pending.

Of every peptide in this guide, MT-2 carries the most serious documented risk profile. The FDA, UK MHRA, Australian TGA, and EMA have all issued explicit consumer warnings against unlicensed Melanotan II. Documented harms include melanoma case reports, mole darkening (which can mask early skin cancer), priapism, severe nausea, and rare cases of posterior reversible encephalopathy syndrome. Available from research peptide vendors; the access bar is technically low. The harm profile is not.

An approved prescription medicine in Russia (nasal spray for stroke recovery, ADHD, cognitive support). In the U.S., available only as a research compound — typically as nasal spray or injectable from research peptide vendors. Independent (non-Russian) human trial data remains very limited.

A vendor-coined combination product, named for the comic book character. No clinical trials of the combination as a unit. The marketing is built on the underlying ingredients, and the regulatory considerations are the union of BPC-157 and TB-500.

Removed from FDA Category 2 in September 2024; PCAC reviewed and voted against adding it to the 503A list. Sold by U.S. research peptide vendors. Worth re-emphasizing: the with-DAC version stays in the body for ~6–8 days; the without-DAC version (Mod GRF 1-29) clears in ~30 minutes. Verify which one you have. Both are sold as "CJC-1295."

Was developed through Phase 2 trials by Helsinn Group for postoperative ileus. Failed primary endpoint; never approved. PCAC voted against 503A inclusion in October 2024. Available as a research compound only.

Approved prescription medicine in 35+ countries (commonly for hepatitis B/C and as an adjunct in cancer immunotherapy). Not FDA-approved in the U.S. PCAC voted against 503A inclusion in December 2024. In the U.S., available only as a research compound — but in countries where it's approved, it's a normal pharmacy item.

An approved prescription nasal spray in Russia for anxiety. No FDA equivalent. Independent (non-Russian) human clinical evidence is very limited. In the U.S., research compound only.

Like Selank, Semax is an approved Russian prescription medicine — in this case for stroke recovery, ADHD, and cognitive support. The U.S. access path is the research peptide gray market (covered in Tier 02). For Russian readers, it's a normal pharmacy purchase.

Eli Lilly's Phase 3 obesity drug. Late-stage trials are running through 2026 (the TRIUMPH program). Expected NDA filing late 2026 / early 2027 with possible approval mid-to-late 2027. The only legitimate U.S. access today is enrollment in an ongoing TRIUMPH trial — search ClinicalTrials.gov. Anything sold online claiming to be "retatrutide" is not the manufacturer's clinical-grade material; it's research-grade synthesis with no oversight or known purity profile.

Used in academic fertility research and in some specialty endocrinology clinics for diagnostic testing of hypogonadism. Not a consumer product. Not sold by mainstream research peptide vendors. The realistic access path is being a participant in academic research or an endocrinology patient at a center using it diagnostically.